ViewRay is in the healthcare sector and is part of the medical devices industry. The company CEO is Scott Drake. ViewRay Inc is a medical device company. The company is engaged in designing, manufacturing and marketing MRI guided radiation therapy system that images and treats cancer patients.
Previous Intraday Performance:
The VRAY shares had a previous change of 2.66% which opened at 8.68 and closed at 8.87. It moved to an intraday high of 8.91 and a low of 8.63.
Over the last five trading days, VRAY shares returned 6.23% and in the past 30 trading days it returned 31.02%. Over three months, it changed 2.54%. In one year it has changed 18.74% and within that year its 52 week high was 13.21 and its 52 week low was 4.86. VRAY stock is 82.51% above its 52 week low.
Our calculations result in a 200 day moving average of 8.00 and a 50 day moving average of 8.00. Right now, VRAY stock is trading 10.85% above its 200 day moving average.
The company has a market cap of $860.0m with 97.0m shares outstanding and a float of 92.7m shares. Trading volume was 456,074 shares and has experienced an average volume of 954,640 shares. Our calculation, using the current average volume and close price, leads me to believe that the liquidity is bad, highly speculative and an investor may want to avoid this stock.
The last annual reported EPS for ViewRay was -0.96 which ended on 31st of December 2018. Based on 5 analyst estimates, the consensus EPS for the next quarter is -0.22.
Below was the last reported quarterly diluted earnings per share:
|1st||Qtr 2019||Reported 05-02-2019:||-0.34|
|4th||Qtr 2018||Reported 03-14-2019:||-0.17|
|3rd||Qtr 2018||Reported 11-08-2018:||-0.39|
|2nd||Qtr 2018||Reported 08-03-2018:||-0.30|
|1st||Qtr 2018||Reported 05-10-2018:||-0.11|
EPS growth is an important number as it indicates the future prospects of ViewRay; the EPS growth rate, as it is usually called, is typically displayed as a percentage, which at this time is hard to estimate, but revenue growth has been -5.30% over the last twelve months.
Indicators Also to Watch:
The beta was calculated to be 0.94.
Based on last reported financials, the company’s return on assets is -47.35%, price-to-sales is 11.18 and price-to-book is 5.92.
Company Score Card:
Results are out of six:
2 : Growth Expectations Result
6 : Financial Safety Result
0 : Past Performance Result
0 : Valuation Result
0 : Dividend Safety Result
2 : Overall Result